In 2nd Appeal, Federal Circuit Affirms PTAB’s Denial Of Pfizer’s Amendments
WASHINGTON, D.C. — Considering a patent dispute between Pfizer Inc. and other biopharmaceutical companies for the second time, a Federal Circuit U.S. Court of Appeals panel affirmed a U.S. Patent Trial...To view the full article, register now.
Already a subscriber? Click here to view full article